I-PLA2 Activation during Apoptosis Promotes the Exposure of Membrane Lysophosphatidylcholine Leading to Binding by Natural Immunoglobulin M Antibodies and Complement Activation by Kim, Sun Jun et al.
 
J. Exp. Med. 
 

 
 The Rockefeller University Press • 0022-1007/2002/09/655/11 $5.00
Volume 196, Number 5, September 2, 2002 655–665
http://www.jem.org/cgi/doi/10.1084/jem.20020542
 
655
 
I-PLA
 
2
 
 Activation during Apoptosis Promotes the Exposure 
of Membrane Lysophosphatidylcholine Leading to Binding 
by Natural Immunoglobulin M Antibodies and
Complement Activation
 
Sun Jun Kim,
 
1 
 
Debra Gershov,
 
2 
 
Xiaojing Ma,
 
1 
 
Nathan Brot,
 
1, 2
 
and Keith B. Elkon
 
3
 
1
 
Department of Microbiology & Immunology and the 
 
2
 
Hospital for Special Surgery, Weill Medical College of Cornell 
University, New York, NY 10021
 
3
 
Division of Rheumatology, University of Washington, Seattle, WA 98195
 
Abstract
 
Deficiency of serum immunoglobulin (Ig)M is associated with the development of a lupus-like
disease in mice. Recent studies suggest that classical complement components facilitate the
clearance of apoptotic cells and that failure to do so predisposes mice to lupus. Since IgM is a
potent activator of the classical complement pathway, we examined IgM binding to dying
cells. IgM, but not IgG, bound to apoptotic T cells through the Fab
 
 
 
 portion of the antibody.
Exposure of apoptotic cell membranes to phospholipase (PL) A2 increased, whereas PLD re-
duced, IgM binding and complement activation. Absorption studies combined with direct
plate binding assays, revealed that IgM antibodies failed to bind to phosphatidyl lipids, but did
 
recognize lysophosphatidylcholine and the phosphorylcholine head group. Both iPLA
 
2
 
 and
cPLA
 
2
 
 are activated during apoptosis. Since inhibition of iPLA2, but not cPLA2, attenuated
IgM binding to apoptotic cells, these results strongly suggest that the endogenous calcium in-
dependent PLA
 
2
 
, iPLA
 
2
 
, is involved in the hydrolysis of plasma membrane phospholipids and
exposure of the epitope(s) recognized by IgM. We propose that recognition of dying cells by
natural IgM antibodies is, in part, responsible for complement activation on dying cells leading
to their safe clearance.
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Introduction
 
Many perturbations of the immune system predispose to
systemic autoimmune diseases such as systemic lupus
erythematosus (for a review, reference 1). Amongst the
possible causes of autoimmunity, recent attention has fo-
cused on defective clearance of dying cells as a potential
source of immunogens. The strongest evidence support-
ing this mechanism is the expression of a lupus-like dis-
ease in mice deficient in the tyrosine kinase, mer (2).
These mice demonstrate increased numbers of apoptotic
cells in lymphoid organs associated with a failure to phago-
cytose apoptotic cells in vitro. The observations that
mice with disruption of genes encoding Dnase 1 (3), C1q
(4), or acute phase proteins (5) also develop lupus and
that C1q and CRP opsonize dying cells for phagocytosis
by macrophages in vitro (6, 7), support the argument that
defective clearance of dying cells predisposes to lupus-
like diseases.
Two independent studies recently reported that mice
deficient in the secreted form of IgM develop lupus-like
autoimmunity (8, 9). This association could be explained
by increased infections, alterations in the composition of
immune complexes, modulation of T or B cell function, or
deficient clearance of self-antigens in serum IgM-deficient
mice. Since we (6, 7) and others (10) have observed that
complement components can be detected on the surface of
apoptotic cells and facilitate their clearance by macro-
phages, we tested the idea that IgM is responsible for com-
plement activation on apoptotic cells. Here, we report
that IgM activates complement on dying cells and that
these antibodies bind to lysophospholipids, particularly
lysophosphatidylcholine.
 
Address correspondence to Keith Elkon, Division of Rheumatology, Box
356428, University of Washington, Seattle, WA 98195. Phone: 206-543-
3414; Fax: 206-685-9397; E-mail: elkon@u.washington.edu 
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Materials and Methods
 
Serologic Reagents and Antibodies.
 
Human serum was obtained
from normal individuals and from patients (provided by M.
Sweetser, University of Washington, Seattle, WA and M. Coo-
per, University of Alabama, Birmingham, AL) with agammaglob-
ulinemia (serum 1) or common variable immune deficiency (se-
rum 2 and 3) and was stored in aliquots at 
 
 
 
70
 
 
 
C. The serum
concentrations (
 
 
 
g/ml) of Igs were: serum 1, IgG
 
   
 
575; IgM 
 
 
 
58; IgA 
 
  
 
7; serum 2, IgG 
 
  
 
42, IgM 
 
  
 
7, IgA 
 
  
 
18; serum 3,
IgG 
 
  
 
51; IgM 
 
  
 
9; IgA 
 
  
 
7 (normal ranges IgG, 6,300–13,000;
IgM, 400–1,000; IgA, 400–1,350). Human sera with IgM anti-
cardiolipin autoantibodies (range 63–300 MPL units) were ob-
tained as described previously (11). Secretory IgM–deficient mice
on a C57BL/6 and 129 backgrounds (8) were provided by J.
Chen (MIT, Cambridge, MA).
Serum depleted of C1q (C1q-D), serum depleted of C8 (C8-
D), mAb to C3b/bi, C1q, and a neoantigen created by the for-
mation of the membrane attack complex (MAC; C5b-9), anti–
Sc5–9, polyclonal goat anti–human C1q were purchased from
Advanced Research Technologies. mAbs against PARP and
 
 
 
2-microglobulin were purchased from BD PharMingen, and
polyclonal antibodies against the following proteins (and their
commercial sources) were as follows: FITC-conjugated anti–
human IgG, IgM (heavy-chain specific), sheep anti–mouse IgG,
HRP-conjugated goat anti–mouse IgG (Jackson ImmunoRe-
search Laboratories); FITC-conjugated goat anti–mouse C3
(ICN). Purified human IgM, trypsin, trypsin inhibitor, hydro-
gen peroxide, and myeloperoxidase were purchased from
Sigma-Aldrich. The mAbs, T15 (anti-phosphorylcholine[PC]
 
*
 
),
SUV (anti-phosphatidyl choline), EO6 (anti-oxidized phospho-
lipid) were provided by M. Scharff, Albert Einstein College of
Medicine, Bronx, NY, R. Hardy, Fox Chase Cancer Center,
Philadelphia, PA, and J. Witztum, UCSD, San Diego, CA, re-
spectively.
 
Trypsin Digestion of IgM.
 
IgM was digested with trypsin at a
ratio of 200:1 (w/w) at 65
 
 
 
C for 20 min and the reaction termi-
nated by the addition of soybean trypsin inhibitor. Fc and Fab
fragments were resolved by Fast Performance Liquid Chromatog-
raphy (FPLC) using a HR16/60 S-300 column (Amersham Phar-
macia Biotech). Purity of each fragment was determined by SDS-
PAGE and Coomassie blue staining.
 
Cells and Induction of Apoptosis.
 
Jurkat T cells or peripheral
blood derived T cells from normal donors were cultured in
RPMI 1640 medium supplemented with 10% FBS, 
 
L
 
-glu-
tamine, and penicillin-streptomycin as described previously
(12). Normal T cells were activated by PHA (5 
 
 
 
g/ml) and 100
U/ml of IL-2. Apoptosis of Jurkat T cells or activated peripheral
blood T cells was induced by incubation with 0.2 
 
 
 
g/ml stauro-
sporine (Sigma-Aldrich) for 6–8 h. 7-h incubation with dexa-
methasone (10
 
 
 
6
 
 M) was used to induce cell death of mouse thy-
mocytes. Necrosis was induced by heat treatment of cells at
65
 
 
 
C for 1 h (13). The percentage of early and late apoptotic
cells was quantified by flow cytometry analysis using Annexin V
and propidium iodide according to the manufacturer’s instruc-
tions (Travigen, Inc.). Distinction between apoptotic and ne-
crotic cells was based on exclusion of trypan blue as determined
by light microscopy. Intracellular caspase-3 activity was quanti-
 
fied by cleavage of the PhiPhiLux-G
 
1
 
D
 
2
 
 substrate (OncoIm-
mune, Inc.) per the manufacturer’s instructions. Nuclear mor-
phology was evaluated by staining cells with bisBENZIMIDE
(2
 
 
 
-[4-Ethoxyphenyl]-5-[4-methyl-1-piperazinyl]-2,5
 
 
 
-bi-1H-
benzimidazole, Hoechst No.33342) and immunofluorescence
microscopy.
 
Complement Activation and Flow Cytometry.
 
Complement
binding and activation studies were performed by incubation of
10
 
6
 
 cells with 100
 
  
 
l of medium containing 20% normal human
serum (NHS) or a hypogammaglobulinemia serum (HGS) in
TC buffer (140 mM NaCl, 2 mM CaCl
 
2
 
, 10 mM Tris, pH 7.4,
supplemented with 1 mM Mg
 
2
 
 
 
 and 1% BSA) for 30 min at
37
 
 
 
C. Cell-bound antibody or complement were detected by
staining cells with FITC-conjugated antibodies for 30 min at
4
 
 
 
C. Flow cytometry was performed on a FACScan™ instru-
ment operating with CELLQuest™ software (Becton Dickin-
son) as described previously (12). Debris was excluded by FCS/
SSC gating. Data were displayed on a logarithmic scale of in-
creasing fluorescence intensity.
 
Western Blot Analysis and Immunoprecipitation.
 
To detect pro-
tein antigens on apoptotic cells, cell membranes were labeled
with D-Biotinyl-E-amidocaproic acid 
 
N
 
-hydroxysuccinimide es-
ter (Pierce Chemical Co.) according to the manufacturer’s in-
structions. Western blot analysis was performed as described pre-
viously (12) and developed using an ECL kit (Amersham
Biosciences) according to the manufacturer’s instructions. The
cells were incubated with 20% NHS or HGS, washed, and im-
munoprecipitated with rabbit IgG anti–human IgM adsorbed to
protein G beads. Immunoprecipitated proteins were resolved by
SDS-PAGE and detected by immunoblotting with streptavidin as
described previously (12). Detection of ribosomal protein P0 (14)
was used as a loading control.
 
Oxidation and Enzymatic Hydrolysis of the Plasma Membrane.
 
Purified human oxidized LDL was obtained from Fred deBeer
(University of Kentucky, Lexington, KY). Live or early apoptotic
PBLs were incubated with 1 
 
 
 
g/ml of myeloperoxidase with or
without 0.5 mM of H
 
2
 
0
 
2
 
 for 30 and 60 min at room temperature
with gentle shaking. The reaction was terminated by adding ice
cold-PBS and extensive washing.
Type I (snake venom) and type III (bee venom) sPLA
 
2
 
, PLD
and propranolol were purchased from Sigma. Enzymatic hydrol-
ysis of intact apoptotic cells with PLs was performed by incuba-
tion of cells with varying concentrations of enzymes for 1 h ei-
ther at 0
 
 
 
 or 37
 
 
 
C. The iPLA
 
2
 
 inhibitor, bromoeonol lactone
(BEL) was purchased from Cayman and the selective sPLA
 
2
 
 in-
hibitor, Shionogi-1 (15), was provided by M. Gelb, University of
Washington, Seattle, WA.
 
Adsorption of Serum IgM by PC or Phospholipid Vesicles Absortion
of Serum by Phospholipid Vesicles.
 
PC chloride (PC-Cl), O-Phos-
phorylethanolamine (PE), and O-Phospho-
 
L
 
-Serine were pur-
chased from Sigma-Aldrich, and PC-KLH from BioResearch
Technologies, Inc. The synthetic phospholipids,1,2-diacyl-
sn-glycero-3-phosphocholine (PtC), 1,2-diacyl-sn-glycero-3-
[phospho-
 
L
 
-serine (PtS), and 1,2-diacyl-sn-3-phosphoethano-
lamine (PtE), 1-acyl-2-hydroxy-sn-glycero-3-phosphocholine
(lysoPtC), 1-acyl-2-hydroxy-sn-glycero-3-phosphoethanolamine
(lysoPtE), and 1-acyl-2-hydroxy-sn-glycero-3-phospho-L-serine
(lysoPtS) were purchased from Avanti Polar Lipids, Inc. Phos-
pholipids were dissolved in chloroform and liposomes prepared
as described previously (16). In brief, the phospholipid solu-
tions were evaporated and dried under a nitrogen stream for 60
min and the lipid film resuspended in PBS, pH 7.4. The suspen-
 
*
 
Abbreviations used in this paper:
 
 BEL, bromoeonol lactone; FPLC, Fast
Performance Liquid Chromatography; HGS, hypogammaglobulinemia
serum; NHS, normal human serum; MAC, membrane attack complex;
PBT, peripheral blood–derived T cell; PC, phosphorylcholine; PE, phos-
phorylethanolamine; PL, phospholipase; PS, phosphorylserine. 
657
 
Kim et al.
 
sion was sonicated using a Misonix sonicator (1 min at 30%
power, for 5–10 cycles on ice). The final applied lipid concentra-
tion was 10 mM.
Antibody absorptions with phospholipid liposomes were per-
formed by incubating 20% serum with varying concentrations
of liposome for 60 min at 37
 
 
 
C. After incubation, serum and
phospholipids were separated by low speed centrifugation
(13,000 rpm 
 
 
 
 10 min). Serum absorption by lysophospholip-
ids was achieved by first coating 96-well plates with lysophos-
pholipids in methanol at 50 
 
 
 
g/ml for 18 h at 4
 
 
 
C. The follow-
ing day, 20% of NHS, HGS, or purified IgM diluted in 1%
BSA/PBS was applied to the plates for 2.5 h and the superna-
tant harvested.
 
Results
 
Serum IgM Binds to Apoptotic Cells and Recruits Comple-
ment.
 
We have previously shown that apoptotic lympho-
cytes activate complement resulting in the deposition of
C3b/bi on the surface of the cells (7). Depending on the
concentration of other serum opsonins such as CRP as well
as the stage of cell death, both early (C1q) and late (the
MAC) complement components may also be observed on
dying cells (7). To examine whether natural antibodies
could be responsible for complement activation on dying
cells, we examined IgM and IgG binding to apoptotic cells.
As shown in Fig. 1 A, IgM, but not IgG, bound to the cell
Figure 1. IgM activates complement on apoptotic cells. (A) Normal peripheral blood–derived T cells (PBT) were either incubated in medium or in-
duced to undergo apoptosis by staurosporine (STS) as described in Materials and Methods. The cells were then incubated with either purified human IgG
(10 mg/ml) or IgM (1 mg/ml) for 20 min at 37 C and examined for Ig binding by flow cytometry (thin line, live cells; thick line, apoptotic cells; dotted
line, apoptotic cells incubated with second antibody alone). The change in mean channel fluorescence ( ) between the cells incubated with second anti-
body alone versus IgG or IgM followed by second antibody is shown. Representative of five experiments. (B) Apoptotic PBT cells were incubated with
either HGS or autologous NHS for 30 min followed by two-color flow cytometric analysis of IgM and C3b/bi binding. Representative of three experi-
ments. (C) Apoptotic PBT cells were incubated with either 20% autologous NHS or HGS no. 2 and 3 for 30 min at 37 C. Deposition of cell surface
C3b/bi and the MAC were quantified by flow cytometry as described in Materials and Methods. As a control for complement activity in the HGS sera,
C3b/bi, and MAC deposition on T cells were quantified after incubation with an IgM monoclonal anti- 2 microglobulin antibody followed by either
NHS or HGS as a source of complement. The results are expressed as complement component binding in HGS/complement component binding in
NHS  100 (mean   SD of 4 experiments). (D) C57BL/6 (B6) thymocytes were incubated with 1  M dexamethasone for 6 h to induce apoptosis.
Apoptotic thymocytes were incubated with 20% of autologous wild-type serum or serum obtained from sIgM /  deficient mice on a B6 or 129 back-
ground for 30 min at 37 C. C3 binding to the cells was quantified by flow cytometry. As a control, C3 deposition was also quantified following preincu-
bation of the apoptotic cells with IgM anti-Thy.1 antibodies. The results are expressed as percentage of complement activation. Two experiments gave
virtually identical results. (E) Apoptotic PBT cells prepared as in C, were incubated with NHS, HGS, or HGS reconstituted with purified human 10 mg/ml
IgG or 1 mg/ml IgM. C3b/bi deposition was detected by flow cytometry and are expressed as the percentage of cells positive for staining (mean   SD of
3 experiments). 
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surface. Furthermore, 
 
 
 
2/3 of C3b/bi-positive apoptotic
cells costained for IgM (Fig. 1 B). Human (Fig. 1, B and C)
and mouse (Fig. 1 D) sera that were deficient in gamma-
globulins (HGS) or secretory IgM (sIgM
 
 
 
/
 
 
 
) respectively,
showed a striking reduction (66–75% in human and 50–
60% in mouse) in complement deposition on the apoptotic
cell surface. These findings could not be explained by ab-
normalities in the HGS or the IgM-deficient sera since
these sera permitted complement recruitment to the surface
of cells sensitized with control IgM antibodies and the re-
constitution of HGS with IgM, but not IgG, restored C3b/
bi deposition on the apoptotic cells (Fig. 1 E).
 
IgM Antibodies Recruit C1q to the Surface of Apoptotic Lym-
phocytes and Promote the Activation of C3.
 
It has previously
been reported that C1q binds strongly to permeabilized ap-
optotic keratinocytes (10) and we have observed weaker
C1q binding to the surface of nonpermeabilized apoptotic
T cells (6). Since IgM activates complement through the
classical pathway and we observed that maximal C3b/bi
deposition on apoptotic cells required classical pathway ac-
tivation (7), we evaluated C1q binding to apoptotic cells by
Western blot analysis. As shown in Fig. 2 A, whereas little
C1q binding was detected on live cells incubated with
NHS (lane 3) or apoptotic cells incubated with HGS (lane
5), strong C1q binding was detected on apoptotic cells in-
cubated with NHS (lane 7) or HGS reconstituted with
normal IgM (lane 6). Furthermore, when isolated compo-
nents were used, the addition of IgM to apoptotic cells
markedly enhanced C1q recruitment to the cell surface
(Fig. 2 B). Together, these findings indicate that IgM is, in
large part, responsible for the activation of the classical
complement pathway on apoptotic cells.
To determine the relative roles of IgM catalyzed versus
IgM-independent activation of C3 on apoptotic cells, we
compared C3b/bi binding on apoptotic cells in serum defi-
cient in C1q or HGS and then reconstituted these sera with
the relevant missing protein. As shown in Fig. 2 C, sera de-
ficient in either C1q or IgM promoted a low, but equiva-
lent, “baseline” C3b/bi binding. The fact that in HGS, re-
constitution with IgM was required to restore C3b/bi
deposition to levels equivalent to normal serum (Fig. 2 C),
strongly reinforces the interpretation that IgM is the limit-
ing factor for C3b/bi deposition on apoptotic cells. The
strikingly parallel curves also suggests that most C3 activa-
tion on apoptotic cells occurs by the same mechanism,
namely IgM recruitment of C1q.
IgM antibodies recognize the potential universe of for-
eign antigens and binding is usually of low affinity (17).
The Fc portion of IgM is heavily glycosylated and may in-
teract with lectins and other structures. To determine
whether IgM binding to apoptotic cells was due to recogni-
tion of antigens by Fab or could be explained by Fc
 
 
 
 inter-
actions with molecules on the surface of the apoptotic cell,
IgM was digested with trypsin, and the FPLC-purified Fab
and Fc
 
 
 
 fragments tested for binding to apoptotic cells. As
shown in Fig. 3, when highly purified Fab and Fc
 
  
 
frag-
ments were tested for binding to apoptotic cells the Fab,
but not the Fc
 
 
 
, fragment bound to the cells. These results
Figure 2. IgM recruits C1q to apoptotic cells leading to C3 activation. (A) Live or
apoptotic PBT cells were incubated with medium alone ( ), NHS, HGS, or HGS
reconstituted with IgM (1 mg/ml) as indicated for 30 min at 37 C. The cells were
washed and C1q binding detected by Western blot analysis as described in Materials
and Methods. For Western blot analysis, protein loading was compared by probing
the same membrane with anti-ribosomal P antiserum (38 kD). Representative of
three experiments. (B) Apoptotic PBT cells were incubated with purified human
IgM (1 mg/ml) as above, washed and then incubated with purified human C1q (10
 g/ml) for 20 min at 37 C. C1q binding on the surface of apoptotic cells was de-
tected by flow cytometry using a monoclonal anti–human C1q antibody. The results
are expressed as the mean   SD of three experiments. (C) Apoptotic PBT cells were incubated as in A. with either NHS, HGS, or HGS to which IgM
was added to the final concentrations ( g/ml) indicated. These concentrations correspond to serial 10-fold dilutions of the normal serum concentration
(1 mg/ml). Parallel experiments were performed with C1q depleted serum (C1q-D) to which serial 10-fold dilutions of C1q were added (normal serum
concentration is 50  g/ ml). C3b/bi binding was detected by flow cytometry and expressed as the percentage of cells positive for staining as in Fig. 1 E
(mean   SD of 3 experiments). 
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cannot be explained by tryptic digestion of the Fc
 
 
 
 epitope
since the antibody recognized the Fc
 
 
 
 fragment on a West-
ern blot (unpublished data). We conclude that IgM binding
to apoptotic cells is due to antigen recognition by Fab.
 
Natural IgM Antibodies Recognize Surface Structures Exposed
on Late Apoptotic Cells.
 
To begin to address the specificity
of the natural antibodies that bound to apoptotic cells, we
first examined the kinetics of IgM binding in relation to
cell surface membrane changes. Whereas almost half of the
apoptotic cells bound annexin V6 h after apoptosis induc-
tion, the kinetics of IgM binding was slower and more
closely approximated entry of PI into the cell (Fig. 4 A).
IgM stained only PI-positive, trypan blue-negative, cells.
Taken together, these findings indicate that IgM antibodies
recognized antigen(s) exposed on late apoptotic cells, but
before substantial disruption of cell membrane integrity.
IgM also bound to heat-induced necrotic cells (unpub-
lished data).
Although purified IgM bound to apoptotic cells, indicat-
ing that complement-mediated damage was not necessary
for antigen exposure, we examined whether complement
activity in NHS influenced IgM binding through MAC in-
duced lysis of the membrane. In three consecutive experi-
ments, the percentage of cells positive for PI (mean 
 
  
 
SE)
was 53
 
    
 
1.3 (NHS) and 52 
 
  
 
2.7 (C8-D) and little
change in IgM binding (NHS 
 
 
 
 26 
 
 
 
 4.8 versus C8-D 
 
 
 
25 
 
  
 
2.8) was observed. These results indicate that com-
plement did not induce significant membrane lysis under
these conditions.
Consistent with the different kinetics of annexin V and
IgM antibody binding to apoptotic cells, PtS-containing li-
posomes minimally inhibited IgM binding (16.28% and
 
 
 
40% at 50 
 
 
 
g/ml and at 500 
 
 
 
g/ml, respectively; Fig. 4
B) and there was a poor correlation between the binding of
IgM to apoptotic cells and the anticardiolipin antibody ac-
tivity as quantified by ELISA (unpublished data). Similarly,
although PtC liposomes absorbed binding of a monoclonal
anti-PtC antibody, the PtC-liposomes failed to absorb nat-
ural antibodies that bound to apoptotic cells (Fig. 4 B). At-
tempts to immunoprecipitate biotinylated cell surface pro-
Figure 3. IgM binds to apop-
totic cells by its Fab domain. Fc
and Fab fragments of IgM were
prepared by tryptic digestion and
were isolated by FPLC as de-
scribed in Materials and Meth-
ods. (A) Purity of the fragments
(20  g per lane) was assessed by
SDS -10% PAGE under reduc-
ing conditions and proteins de-
tected by Commassie-Blue stain-
ing. Lane 1, molecular mass
standards; lane 2, IgM before di-
gestion; lane 3, Fc ; lane 4,
Fab . (B) Isolated IgM, IgM
heated to 65 C for 10 min, IgM
Fc  or Fab  fragments (all tested at a concentration of 1 pM) were examined for binding to apoptotic PBT as in Fig. 1 except that IgM Fc or Fab  bind-
ing were detected with polyclonal antibodies specific for the fragment. The results are expressed as the mean   SD of four experiments.
Figure 4. Kinetics and specificity of IgM binding to apoptotic cells. (A) Apoptosis of PBT cells was induced as in Fig. 1 and at time 0, 2, 4 and 6 h, the
cells were incubated in medium containing 20% NHS or HGS. Cells were analyzed by flow cytometry for Annexin V or IgM binding as well as for per-
meability to PI and trypan blue as indicated in the Figure. The results are expressed as the percentage of cells positive. The results are expressed as the
mean   SD of three experiments. (B) Purified IgM was incubated with liposomes containing either 50 or 500 ug/ml PtS or PtC for 30 min at 37 C.
Samples were centrifuged and the supernates tested for binding to apoptotic cells. Annexin V and SUV (an anti-PtC specific mAb), were used as positive
controls for binding to PtS and PtC, respectively. The results are expressed as percentage of inhibition of binding, calculated from (binding in medium  
binding after preadsorbtion with liposome/binding in medium)   100. The results are expressed as the mean   SD of three experiments.660 Natural IgM Antibodies Bind to Phospholipids on Apoptotic Cells
teins with IgM or Western blot analysis of apoptotic cell
extracts failed to reveal protein or glycoprotein antigens
(unpublished data).
Natural IgM Antibodies Bind to Lysophospholipids on Apop-
totic Cells and Have Specificity for PC. In addition to trans-
location of phosphorylserine (PS), alterations such as oxi-
dation (18, 19) or action of PLs (20) could effect exposure
of antigens to the outer cell surface membrane of apop-
totic cells. Wiztum and colleagues (21) reported that cer-
tain murine natural antibodies, including the classic T15
mAb (22), bind to oxidized LDL and to the surface of ap-
optotic endothelial cells (23, 21). When we preincubated
IgM with intentionally oxidized apoptotic cells or oxi-
dized LDL, IgM binding was reduced by 15   2% (un-
published data). This indicates that only a small subset of
IgM antibodies had a specificity identical to the mAbs de-
scribed above. In contrast, exposure of apoptotic cells to
sPLA2, that catalyzes the hydrolysis of the sn-2 fatty acyl
bond to form lysophosphopholipids, markedly increased
IgM binding to human apoptotic cells (Fig. 5 A). sPLA2
exerted a similar effect on C3 binding to murine apoptotic
cells which was considerably greater in wild-type com-
pared with IgM deficient sera. (Fig. 5 B). Since some C3
was deposited on sPLA2 treated apoptotic cells incubated
in IgM deficient serum, the altered cell surface must also
activate the alternative or/and MBL complement path-
ways, albeit less efficiently than the classical pathway. By
comparing C3b/bi deposition on apoptotic cells in the
presence or absence of C1q, we observed that  1/3 of
C3b/bi deposition occurred independently of classical
pathway in cells exposed to medium or to sPLA2 (unpub-
lished data).
The findings above suggested the possibility that IgM
antibodies bound to lysophospholipids but the results could
also be explained by an effect of PLA2 increasing mem-
brane exposure to an unrelated antigen. To determine
whether IgM was directly targeting lysophospholipids, ap-
optotic cells were incubated with PLD, an enzyme that
cleaves the head groups from phospholipids. As shown in
Fig. 5, A and B, PLD strikingly reduced IgM (Fig. 5 A) and
C3 binding to apoptotic cells suggesting that the antibodies
had specificity for the polar head group of phospholipids.
To further address IgM specificity, IgM was preabsorbed
with lysophosphatidylcholine (lysoPtC), lysophosphati-
dylserine (lysoPtS), or lysophosphatidylethanolamine (lyso-
PtE) containing micelles. However, these results were
Figure 5. IgM antibodies bind to components of lysophospholipids on the cell surface membrane. (A) Apoptotic cells were incubated in medium alone
or medium containing 1 U of PLs (PLA2 or PLD) for 30 min at 37 C or on ice (0 C). The cells were washed and then incubated with purified IgM or
the TEPC15 anti-PC mAb for 20 min at 37 C. IgM binding to live cells is shown for comparison. Antibody binding was detected by flow cytometry and
is expressed as the mean   SD of 4 experiments. (B) Thymocytes were rendered apoptotic as in Fig. 1 and then exposed to 1U of type I or type III sPLA2
or 1U PLD for 30 min at 37 C. They were then washed and incubated with wild-type (WT) or IgM-deficient (sIgM / ) serum followed by flow cy-
tometry analysis for C3 binding. The results are expressed as the percentage of cells staining for C3 and are representative of two experiments. Cells incu-
bated with heat-inactivated serum (HIS) or anti-Thy1 were used as negative and positive controls, respectively. (C) NHS was incubated with solid phase
adsorbed lysophospholipids and then tested for binding to apoptotic cells. The results are expressed as inhibition of IgM binding, calculated as in Fig. 4
and are the mean   SD of 3 experiments. (D) NHS was preincubated with varying concentration of PC, PS, or PE as shown for 30 min at 37 C. Inhi-
bition of IgM binding to apoptotic cells was calculated as above. The results are expressed as the mean   SD of 3 experiments. (E) Purified IgM or NHS
was incubated with PC (PC-Cl) and the percentage inhibition of IgM binding to apoptotic cells determined by flow cytometry as in C. TEPC15, and an
anti- 2 microglobulin mAb, were used as positive and negative controls, respectively. The results are expressed as the mean   SD of 4 experiments.661 Kim et al.
inconclusive due to the high detergent activity of residual
lysophospholipids on apoptotic cells. As an alternative ap-
proach, IgM was preabsorbed on plates coated with lyso-
phospholipids and the supernates tested for binding to ap-
optotic cells. As shown in Fig. 5 C, whereas preadsorption
with lysoPtE and lysoPtS had little effect, preadsorption
with lysoPtC resulted in  50% inhibition of IgM binding
to apoptotic cells. These results support the observation
that IgM bound to lysophospholipids on apoptotic cells and
indicate that a significant proportion of the antibodies
bound to lysoPtC.
Loss of antibody binding to PLD-treated apoptotic cells
suggested that IgM antibodies recognized the polar head
group of lysophospholipids. To examine this directly, IgM
was pre incubated with PC, PE or PS and tested for bind-
ing to apoptotic cells. As shown in (Fig. 5 D), PC, but not
PS or PE, reduced IgM binding to apoptotic cells in a
dose-dependent response. Inhibition was relatively specific
in that preincubation of anti- 2 microglobulin with PC
had no effect on binding (Fig. 5 E). Taken together with
the results above, these findings indicate that a substantial
fraction of the polyclonal IgM in human serum that binds
to apoptotic cells recognizes lysoPtC.
Inhibition of iPLA2 Attenuates IgM Binding to Apoptotic
Cells. PLA2 has been implicated in membrane remodel-
ing during apoptosis (24, 25). To determine whether en-
dogenous PLs were responsible for inducing the cell mem-
brane changes that led to the binding of IgM, inhibitors of
PLA2 were used to attenuate PLA2 hydrolysis. BEL (an in-
hibitor of the Ca2 -independent type VI PLA2, iPLA2),
but not Shionogi-1 (an inhibitor of Ca2 -dependent type
IV PLA2, cPLA2) attenuated the binding of both IgM (Fig.
6 A) and annexin V (Fig. 6 B) to the cell surface mem-
brane. This effect on the cell membrane can be attributed
to attenuation of iPLA2 rather than phosphatidate phospho-
hydrolase, because propranolol failed to effect binding
of either IgM or annexin V (26). To determine whether at-
tenuation of IgM binding by BEL could be due to a gen-
eral inhibition of apoptosis, rather than a selective surface
membrane effect, we asked whether BEL impeded other
downstream effects of the apoptotic cascade. Since BEL did
not inhibit cleavage of the caspase-3 substrates, Phi-phi Lux
or PARP nor did it attenuate nuclear condensation (Fig. 6,
C–E), we conclude that the BEL effect on cell surface
membranes of apoptotic cells was relatively selective. In
sum, these results strongly suggest that the endogenous cal-
Figure 6. BEL, an inhibitor of endogenous iPLA2 attenuates IgM binding to apoptotic cells. (A) PBMT were incubated with staurosporine together
with medium alone or medium containing the PLA2 inhibitors, 10  M BEL or 5  M Shionogi-1 for 6 h (A and C) or the phosphatidate phosphohydro-
lase inhibitor, propranolol (12.5  M) (B). The cells were then stained with Annexin V-FITC (A and B) and/or purified human IgM followed by
FITC-anti–human IgM (B). To determine the effects of BEL on intracellular apoptotic events, cells were examined for caspase-3 activity by flow cytom-
etry (C), PARP cleavage by Western blot analysis (D), or nuclear condensation by Hoechst staining and immunofluorescence (E) in the presence or ab-
sence of 10  M BEL as described in Materials and Methods. For Western blot analysis (D), protein loading was compared by probing the same membrane
with antiribosomal P antiserum (38 kD). A–C are mean   SD of 3 experiments; D and E are representative of two experiments with identical results.662 Natural IgM Antibodies Bind to Phospholipids on Apoptotic Cells
cium independent PLA2, iPLA2, is involved in the hydroly-
sis of plasma membrane phospholipids and exposure of the
epitope(s) recognized by IgM.
Discussion
Previous studies have shown that complement op-
sonization is required for efficient phagocytosis of dying
cells in vitro (6, 7) and that uptake of these opsonized cells
is associated with expression of the antiinflammatory cy-
tokine, TGF-  (6). Three observations, namely that C1q
binds to apoptotic cells in vitro (10), that apoptotic cells
accumulate in the kidneys of mice deficient in C1q (4),
and that complement activation on apoptotic cells pro-
motes phagocytosis of these cells by macrophages in vitro,
suggest a pivotal role for complement in noninflammatory
clearance of dying cells. Here, we report that IgM anti-
bodies in normal individuals are quantitatively most im-
portant for C1q binding and C3b/bi activation on the ap-
optotic cell surface and that these natural antibodies bind
to lysophosphorylcholine that is exposed on cells under-
going apoptosis.
Since IgM bound to apoptotic cells by the Fab, rather
than the Fc, portion of the Ig, binding could be attributed
to antibody recognition of an antigen(s) exposed on dying
cells. A potential candidate antigen was PS, a membrane
phospholipid that translocates from the inner to the outer
side of the cell membrane during apoptosis and is recog-
nized by at least some anticardiolipin autoantibodies that
occur in the serum of patients with diseases such as systemic
lupus erythematosus (27, 28). Failure of PS-containing li-
posomes to absorb IgM reactivity, and the lack of a correla-
tion between anticardiolipin autoantibody titers and IgM
binding to apoptotic cells, indicated that the apoptotic cell-
reactive IgM antibodies and anticardiolipin autoantibodies
had different specificities.
Failure to identify cell surface protein autoantigens by
immunoprecipitation or by Western blot analysis suggested
that IgM antibodies were binding to nonprotein antigens
exposed on apoptotic cell membranes. Clues to the speci-
ficity of the IgM antibodies were provided by enzymatic
hydrolysis of membrane components and antibody inhibi-
tion experiments. Apoptotic cell membranes are known to
be highly susceptible to type II sPLA2, resulting in the hy-
drolysis of membrane phospholipids and the release of
arachidonic acid (29). Incubation of apoptotic cells with ei-
ther type II or type III sPLA2 strikingly increased IgM and
C3 binding to the cell surface. This finding suggested that
the IgM antibodies recognized lysophospholipid(s) gener-
ated by PLA2 itself or recognized other structures made
more accessible by membrane disruption.
To distinguish between these two possibilities, we ex-
posed apoptotic cells to PLD, a lipase that removes the
head group from phospholipids. The striking loss of reac-
tivity of both IgM and C3 binding to PLD treated apop-
totic cells coupled with the inhibition of IgM binding by
PC-Cl, PC- KLH, and lyso-PC (but not by PE nor PS)
strongly suggested that IgM antibodies in normal sera di-
rectly and, relatively selectively, target the PC moiety on
lysophosphatidylcholine. This specificity is strikingly simi-
lar to that described for CRP (30), an acute phase protein
that is also implicated in the clearance of self-antigens dur-
ing inflammation and tissue injury (31). Based on observa-
tions in HGS or IgM-deficient sera, it should be noted that
25–50% of C3 binding to apoptotic cells occurred inde-
pendently of IgM, presumably indicating that CRP or
other complement activators were responsible. Quantita-
tive estimates of the contribution of classical versus other
Figure 7. Proposed role of
IgM in the binding and clearance
of apoptotic cells. Apoptotic cells
activate iPLA2, which results in
exposure of lysophospholipids,
including lyso-PtC, on the cell
membrane. Under normal cir-
cumstances, lysoPtC is recog-
nized by IgM which activates the
classical complement pathway
(A). As shown, not all comple-
ment activation is IgM depen-
dent. Macrophages or dendritic
cells phagocytose complement-
coated cells, and produce immu-
nosuppressive cytokines such as
TGF-  (see references 50, 6, and
54; A). In contrast, when little
IgM is available (B), either the
cells undergo post-apoptotic ne-
crosis and/or are seen by IgG an-
tibodies. In either case, phago-
cytosis of this cargo leads to
proinflammatory cytokine pro-
duction (see references 50, and
6) and, possibly, maturation of
dendritic cells (reference 55).663 Kim et al.
pathways of C3 binding to apoptotic cells revealed that al-
ternative (7) and/or MBL (32) pathways contributed  1/3
of C3b/bi binding.
Previous studies have suggested that some natural anti-
bodies have specificity for phospholipids. All strains of mice
produce idiotypically restricted anti-PtC, predominantly by
B1 B cells (33, 34). Witztum and colleagues demonstrated
that  30% of IgM mAbs that develop spontaneously in
Apo-E deficient mice, bind to oxidized LDL (35). Further-
more, a subset of these monoclonal antibodies (EO6)
bound to apoptotic porcine aortic endothelial cells (23).
Since the EO6 IgM anti-oxLDL antibodies were also inhib-
ited by PC (21), these antibodies bear striking similarities to
the IgM autoantibodies detected in the current study.
However, the IgM antibodies reported here were mini-
mally absorbed by intentionally oxidized apoptotic cells or
oxLDL suggesting subtle differences in binding specificity.
Recent studies have shown that, amongst the 10 groups
of PLA2, the calcium-independent type VIA cytosolic
PLA2, iPLA2, plays an important role in lipid remodeling
(36). Although both cPLA2 and iPLA2 are cleaved by
caspase-3 during apoptosis, the cleaved form of cPLA2 acts
as a dominant negative inhibitor of function whereas
cleaved iPLA2 activity is increased resulting in increased
phospholipid turnover (37), although the precise roles of
cPLA2 and iPLA2 may be cell type and context specific (for
a review, see reference 20). BEL is a PLA2 inhibitor that
has 1,000-fold greater selectivity for iPLA2 compared with
either cPLA2 or sPLA2 (38, 39). Here, we demonstrate that
BEL significantly attenuated cell surface membrane changes
such as PtS exposure on apoptotic cells consistent with a
previous studies (37). Associated with this membrane alter-
ation, IgM binding to apoptotic cells was reduced by
 50%. This finding indicates that activation of endogenous
iPLA2 during apoptosis contributes to exposure of the
phospholipid antigen, lyso-PC, on the cell surface. Fur-
thermore, it supports the identity of lyso-PC as an antigen
recognized by IgM antibodies since antisense studies re-
vealed that iPLA2 selectively inhibited steady-state levels of
cellular lyso-PtC (40).
Numerous studies in the past have suggested that at least
some IgM antibodies in normal individuals have autoreac-
tivity. Examples include low titer anti-ssDNA (41), rheu-
matoid factor, and antibodies reactive with bromelain-
treated red blood cells (42, 34). In mice, reactivity to self
appears to be more prominent with IgM antibodies pro-
duced by CD5  B1 lymphocytes that are most abundant in
the peritoneum (43–45). Of particular relevance to this
study, anti-PC antibodies are detected in normal mouse se-
rum (46) as well as NHS (46). The relationship between
anti-PC and autoantibodies has long been of interest. A
single base change in the S37 T15 idiotype positive hybrid-
oma, altered the specificity of the antibody from PC to
DNA. In addition, some anti-DNA antibodies cross react
with PC (47). Although it has been suggested that anti-PC
antibodies generated in response to pneumococcal infec-
tions may mutate to anti-DNA leading to disease (48), vac-
cination with pneumococcal polysaccharide failed to in-
duce anti-DNA antibodies in humans (47).
The findings in the current manuscript offer a possible
different explanation for the origin and function of anti-
PC antibodies in health and disease (Fig. 7). Under normal
circumstances, anti-PC antibodies would perform a house-
keeping role by promoting the clearance of dying cells
through activation of classical complement pathway. If,
however, classical complement components or opsonins
such as the acute phase protein, CRP, are limiting, IgM
would bind to dying cells but the cells would be ineffi-
ciently cleared leading to postapoptotic necrosis and/or
coating by IgG antibodies (IgG antibodies are produced,
albeit with delayed kinetics, in serum IgM-deficient mice
(49). Phagocytosis of necrotic cells (50) or engagement of
macrophage Fc receptors by IgG (51) leads to production
of proinflammatory cytokines, including TNF- . CRP (6)
and IgM bind to necrotic cells, but do not prevent proin-
flammatory cytokine production since production seems
to be initiated by other pathways (52). These cytokines ac-
tivate and lead to the differentiation of antigen presenting
cells (53) promoting the engagement of low affinity self-
reactive T lymphocytes. This scenario could readily pro-
mote a T cell driven anti-PC response with the potential
for isotype switching to IgG and for somatic mutation.
Whether anti-PC antibodies described here are germ line
encoded and positively selected, whether they bind to bac-
terial PC and whether they can evolve to become anti-
DNA autoantibodies are important questions that remain
to be determined.
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